A novel immunotoxin – rCCK8PE38 targeting of CCK-R overexpressed colon cancers

References

• Gupta AK, Varshney K, Saxena AK. Toward the identification of a reliable 3D QSAR pharmacophore model for the CCK2 receptor antagonism. J Chem Inf Model 2012;52:1376–90
   PubMed Web of Science ®Google Scholar
• Foucaud M, Archer-Lahlou E, Marco E, et al. Insights into the binding and activation sites of the receptors for cholecystokinin and gastrin. Regul Pept 2008;145:17–23
   PubMed Web of Science ®Google Scholar
• Katsouni E, Zarros A, Skandali N, et al. The role of cholecystokinin in the induction of aggressive behavior: a focus on the available experimental data (review). Acta Physiol Hung 2013;100:361–77
   PubMed Web of Science ®Google Scholar
• Staljanssens D, Azari EK, Christiaens O, et al. The CCK(-like) receptor in the animal kingdom: functions, evolution and structures. Peptides 2011;32:607–19
   PubMed Web of Science ®Google Scholar
• Brabez N, Nguyen KL, Saunders K, et al. Synthesis and evaluation of cholecystokinin trimers: a multivalent approach to pancreatic cancer detection and treatment. Bioorg Med Chem Lett 2013;23:2422–5
   PubMed Web of Science ®Google Scholar
• Dufresne M, Seva C, Fourmy D. Cholecystokinin and gastrin receptors. Physiol Rev 2006;86:805–47
   PubMed Web of Science ®Google Scholar
• Morton M, Prendergast C, Barrett TD. Targeting gastrin for the treatment of gastric acid related disorders and pancreatic cancer. Trends Pharmacol Sci 2011;32:201–5
   PubMed Web of Science ®Google Scholar
• Rai R, Chandra V, Tewari M, et al. Cholecystokinin and gastrin receptors targeting in gastrointestinal cancer. Surg Oncol 2012;21:281–92
   PubMed Web of Science ®Google Scholar
• Tornesello AL, Aurilio M, Accardo A, et al. Gastrin and cholecystokinin peptide-based radiopharmaceuticals: an in vivo and in vitro comparison. J Pept Sci 2011;17:405–12
   PubMed Web of Science ®Google Scholar
• Roosenburg S, Laverman P, van Delft FL, et al. Radiolabeled CCK/gastrin peptides for imaging and therapy of CCK2 receptor-expressing tumors. Amino Acids 2011;41:1049–58
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Arons E, Stetler-Stevenson M, et al. Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia. Leuk Lymphoma 2011;52:82–6
   PubMed Web of Science ®Google Scholar
• Weldon JE, Pastan I. A guide to taming a toxin – recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. FEBS J 2011;278:4683–700
   PubMed Web of Science ®Google Scholar
• Haso W, Lee DW, Shah NN, et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood 2013;121:1165–74
   PubMed Web of Science ®Google Scholar
• Baskar S, Wiestner A, Wilson WH, et al. Targeting malignant B cells with an immunotoxin against ROR1. mAbs 2012;4:349–61
   PubMed Web of Science ®Google Scholar
• Chandramohan V, Bao X, Keir ST, et al. Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy. Clin Cancer Res 2013;19:4717–27
   PubMed Web of Science ®Google Scholar
• Chandramohan V, Sampson JH, Pastan I, et al. Toxin-based targeted therapy for malignant brain tumors. Clin Dev Immunol 2012;2012:480429
   PubMedGoogle Scholar
• Singh R, Zhang Y, Pastan I, et al. Synergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with chemotherapy. Clin Cancer Res 2012;18:152–60
   PubMed Web of Science ®Google Scholar
• Wayne AS, Fitzgerald DJ, Kreitman RJ, et al. Immunotoxins for leukemia. Blood 2014;123:2470–7
   PubMed Web of Science ®Google Scholar
• Wayne AS, Kreitman RJ, Findley HW, et al. Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin Cancer Res 2010;16:1894–903
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Pastan I. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res 2011;17:6398–405
   PubMed Web of Science ®Google Scholar
• Liu W, Onda M, Lee B, et al. Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes. Proc Natl Acad Sci USA 2012;109:11782–7
   PubMed Web of Science ®Google Scholar
• Song J, Ren H, Li Y, et al. rG17PE38, a novel immunotoxin target to gastric cancer with overexpressed CCK-2R. J Drug Target 2013;21:375–82
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhang YY, Shen QF, et al. Development of a novel antibody probe useful for domoic acid detection. Biosens Bioelectron 2009;24:3159–63
   PubMed Web of Science ®Google Scholar
• Wayua C, Low PS. Evaluation of a cholecystokinin 2 receptor-targeted near-infrared dye for fluorescence-guided surgery of cancer. Mol Pharm 2013;11:468–76
   PubMed Web of Science ®Google Scholar
• Beinfeld MC. Biosynthesis and processing of pro CCK: recent progress and future challenges. Life Sci 2003;72:747–57
   PubMed Web of Science ®Google Scholar
• Mazor R, Eberle JA, Hu X, et al. Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes. Proc Natl Acad Sci USA 2014;111:8571–6
   PubMed Web of Science ®Google Scholar
• Susan R, Peter L, Floris LD, et al. Radiolabeled CCK/gastrin peptides for imaging and therapy of CCK2 receptor-expressing tumors. Amino Acids 2011;41:1049–58
   PubMed Web of Science ®Google Scholar